Filing Flows › Neogenomics (NEO) › Stock forecast & fair value
Neogenomics (NEO) stock forecast and price target
Neogenomics (NEO) trades at $16.84. 10 analysts' median price target is $22.00 (+31%), from $19.00 to $35.00.
Neogenomics' latest quarter
Neogenomics, Q3 2026: revenue $209M (+11% year over year), operating margin -3.8%, net loss $7.5M, operating cash flow −$8.9M. The chart follows the revenue to costs, profit and cash.
Questions
What is the price target for NEO stock?
The median of 10 analysts' 12-month targets is $22.00, +31% from $16.84; the range is $19.00 to $35.00. The average rating is buy.
Does Neogenomics usually beat earnings estimates?
It beat the consensus EPS estimate in 100% of the quarters on record.
Is NEO stock a buy?
Filing Flows does not give advice. It shows what analysts expect, what each valuation method implies and the figures behind them, read from SEC filings, so you can judge for yourself.
Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.